A bio-imaging signature as a predictor of clinical outcomes in locally advanced pancreatic cancer by Fiore, Michele et al.








A bio-imaging signature as a predictor of clinical outcomes in locally
advanced pancreatic cancer
Fiore, Michele ; Taralli, Silvia ; Trecca, Pasquale ; Scolozzi, Valentina ; Marinelli, Luca ; Triumbari,
Elizabeth K A ; Caputo, Damiano ; Angeletti, Silvia ; Ciccozzi, Massimo ; Coppola, Alessandro ; Greco,
Carlo ; Ippolito, Edy ; Calcagni, Maria Lucia ; Coppola, Roberto ; Ramella, Sara
Abstract: Purpose: To evaluate the predictive value of 18F-FDG PET/CT semiquantitative parameters
of the primary tumour and CA 19-9 levels assessed before treatment in patients with locally advanced
pancreatic cancer (LAPC). Methods: Among one-hundred twenty patients with LAPC treated at our
institution with initial chemotherapy followed by curative chemoradiotherapy (CRT) from July 2013 to
January 2019, a secondary analysis with baseline 18F-FDG PET/CT was conducted in fifty-eight patients.
Pre-treatment CA 19-9 level and the maximum standardized uptake value (SUVmax), metabolic tumour
volume (MTV) and total lesion glycolysis (TLG) of primary tumour were measured. The receiving
operating characteristics (ROC) analysis was performed to define the cut-off point of SUVmax, MTV,
TLG and CA 19-9 values to use in prediction of early progression (EP), local progression (LP) and overall
survival (OS). Areas under the curve (AUCs) were assessed for all variables. Post-test probability was
calculated to evaluate the advantage for parameters combination. Results: For EP, CA 19-9 level > 698
U/mL resulted the best marker to identify patient at higher risk with OR of 5.96 (95% CI, 1.66-19.47; p
= 0.005) and a Positive Predictive Value (PPV) of 61%. For LP, the most significant parameter was TLG
(OR 9.75, 95% CI, 1.64-57.87, p = 0.012), with PPV of 83%. For OS, the most significant parameter
was MTV (OR 3.12, 95% CI, 0.9-10.83, p = 0.07) with PPV of 88%. Adding consecutively each of
the other parameters, PPV to identify patients at risk resulted further increased (>90%). Conclusions:
Pre-treatment CA 19-9 level, as well as MTV and TLG values of primary tumour at baseline 18F-FDG
PET/CT and their combination, may represent significant predictors of EP, LP and OS in LAPC patients.
DOI: https://doi.org/10.3390/cancers12082016






The following work is licensed under a Creative Commons: Attribution 4.0 International (CC BY 4.0)
License.
Originally published at:
Fiore, Michele; Taralli, Silvia; Trecca, Pasquale; Scolozzi, Valentina; Marinelli, Luca; Triumbari, Eliza-
beth K A; Caputo, Damiano; Angeletti, Silvia; Ciccozzi, Massimo; Coppola, Alessandro; Greco, Carlo;
Ippolito, Edy; Calcagni, Maria Lucia; Coppola, Roberto; Ramella, Sara (2020). A bio-imaging signature





A Bio-Imaging Signature as a Predictor of Clinical
Outcomes in Locally Advanced Pancreatic Cancer
Michele Fiore 1,* , Silvia Taralli 2 , Pasquale Trecca 1, Valentina Scolozzi 2, Luca Marinelli 3 ,
Elizabeth K. A. Triumbari 2,4, Damiano Caputo 5 , Silvia Angeletti 6, Massimo Ciccozzi 7,
Alessandro Coppola 5 , Carlo Greco 1, Edy Ippolito 1, Maria Lucia Calcagni 2,4,
Roberto Coppola 5 and Sara Ramella 1
1 Radiation Oncology, Campus Bio-Medico University, 00128 Rome, Italy; p.trecca@unicampus.it (P.T.);
c.greco@unicampus.it (C.G.); e.ippolito@unicampus.it (E.I.); s.ramella@unicampus.it (S.R.)
2 UOC Medicina Nucleare, Fondazione Policlinico Universitario A. Gemelli IRCCS, 00168 Rome, Italy;
silvia.taralli@hotmail.it (S.T.); valentina.scolozzi1@guest.policlinicogemelli.it (V.S.);
elizabethkatherine.triumbari01@icatt.it (E.K.A.T.); marialucia.calcagni@unicatt.it (M.L.C.)
3 Radiation Oncology, S. Andrea Hospital, Sapienza University of Rome, 00189 Rome, Italy;
luca.marinelli@uniroma1.it
4 Istituto di Medicina Nucleare, Università Cattolica del Sacro Cuore, 00168 Rome, Italy
5 Department of Surgery, Campus Bio-Medico University, 00128 Rome, Italy; d.caputo@unicampus.it (D.C.);
a.coppola@unicampus.it (A.C.); r.coppola@unicampus.it (R.C.)
6 Unit of Clinical Laboratory Science, Campus Bio-Medico University, 00128 Rome, Italy;
s.angeletti@unicampus.it
7 Unit of Medical Statistic and Molecular Epidemiology, Campus Bio-Medico University, 00128 Rome, Italy;
m.ciccozzi@unicampus.it
* Correspondence: m.fiore@unicampus.it; Tel.: +39-339-685-4708; Fax: +39-062-2541-1989
Received: 4 July 2020; Accepted: 22 July 2020; Published: 23 July 2020


Abstract: Purpose: To evaluate the predictive value of 18F-FDG PET/CT semiquantitative parameters
of the primary tumour and CA 19-9 levels assessed before treatment in patients with locally advanced
pancreatic cancer (LAPC). Methods: Among one-hundred twenty patients with LAPC treated at our
institution with initial chemotherapy followed by curative chemoradiotherapy (CRT) from July 2013
to January 2019, a secondary analysis with baseline 18F-FDG PET/CT was conducted in fifty-eight
patients. Pre-treatment CA 19-9 level and the maximum standardized uptake value (SUVmax),
metabolic tumour volume (MTV) and total lesion glycolysis (TLG) of primary tumour were measured.
The receiving operating characteristics (ROC) analysis was performed to define the cut-off point
of SUVmax, MTV, TLG and CA 19-9 values to use in prediction of early progression (EP), local
progression (LP) and overall survival (OS). Areas under the curve (AUCs) were assessed for all
variables. Post-test probability was calculated to evaluate the advantage for parameters combination.
Results: For EP, CA 19-9 level > 698 U/mL resulted the best marker to identify patient at higher risk
with OR of 5.96 (95% CI, 1.66–19.47; p = 0.005) and a Positive Predictive Value (PPV) of 61%. For LP,
the most significant parameter was TLG (OR 9.75, 95% CI, 1.64–57.87, p = 0.012), with PPV of 83%.
For OS, the most significant parameter was MTV (OR 3.12, 95% CI, 0.9–10.83, p = 0.07) with PPV
of 88%. Adding consecutively each of the other parameters, PPV to identify patients at risk resulted
further increased (>90%). Conclusions: Pre-treatment CA 19-9 level, as well as MTV and TLG values
of primary tumour at baseline 18F-FDG PET/CT and their combination, may represent significant
predictors of EP, LP and OS in LAPC patients.
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1. Introduction
Pancreatic cancer is one of the most harmful gastrointestinal cancers, whose worldwide incidence
is consistently increasing, with a 5-year survival rate under 5% [1]. At the time of diagnosis, radical
surgery is taken into account only in less than 20% of cases. Almost 30% of patients have a locally
advanced pancreatic cancer (LAPC), the remaining patients present distant metastases [2]. Indeed,
the wide local spread of the tumour to surrounding vascular structures, which is an exclusion criterion
for radical surgical resection (R0), has driven endeavours to reduce tumour size and vascular invasion
of the disease with the combination of chemotherapy and radiotherapy as first line treatment option.
Both loco-regional and distant recurrence are common [3,4], and this suggests that local and systemic
therapies have to be combined. Currently, induction chemotherapy followed by chemoradiotherapy
(CRT) is the strategy considered for curative intent in patients with locally advanced unresectable
cancers, or as neoadjuvant setting in borderline resectable disease [5,6]. The motivation behind
neoadjuvant therapy incorporates a higher rate of R0 resections, improved local control, metastatic
lymph nodes sterilization, and better selection of patients who may receive a surgical resection if
appropriate [7,8]. In recent years, there have been advances in pancreatic imaging. For the assessment of
resectability and tumour spread, multi-detector CT with 3-dimensional reconstruction is the best staging
modality. Additionally, 18F-Fluorodeoxyglucose (18F-FDG) Positron Emission Tomography/Computed
Tomography (PET/CT) plays a role in detecting distant metastases and in evaluating response to
treatment. Moreover, it is also a promising tool for the definition of radiotherapy target volume.
For radiotherapy planning, metabolic data obtained from 18F-FDG PET/CT produces a significant
change in volume definition by identifying sub-volumes of treatment that may benefit from radiation
dose boosting [9]. The role of 18F-FDG PET/CT for the optimization of treatment in pancreatic
cancer is rising, not only for its implementation in radiotherapy planning, but also for its potential
prognostic value. The high mortality rate of pancreatic cancer is related to local tumour progression
and complications of distant metastases. In order to decrease the number of patients who do not
respond to treatment or relapse, the early identification of specific pre-treatment factors as prognostic
predictors may improve patient stratification and personalized treatments. The maximum standardized
uptake value (SUVmax) is the most well-known and commonly used PET-derived semiquantitative
parameter to measure the metabolic activity within a tumour lesion, representing the maximum value
of tracer uptake in the tumour [10]. Several studies have investigated the prognostic role of SUVmax
in pancreatic cancer and additionally upheld the introduction of other semiquantitative volume-based
PET parameters, such as metabolic tumour volume (MTV) and total lesion glycolysis (TLG), with
heterogeneity in population size, treatments and results [11,12]. Recently, a meta-analysis has shown
that these metabolic parameters derived from pre-treatment 18F-FDG PET/CT may play a predictive role
for patients with pancreatic cancer [13]. Moreover, serum carbohydrate antigen (CA) 19-9 has also been
studied for its prognostic value [14]. It is the most common and validated diagnostic tumour marker
and is currently being applied in clinical practice for prediction of treatment response and prognosis.
The combination of induction chemotherapy followed by chemoradiation is increasingly being
used in patients with LAPC. However, there are a group of patients with early progress despite this
treatment intensification, leading to an unfavourable cost-benefit ratio. Early progression can be a useful
indicator in clinical practice. The question this analysis tries to answer is whether integrating humoral
and functional imaging features before treatment may identify high-risk patients for progression, in
whom alternative strategies could then be applied.
2. Materials and Methods
2.1. Patients
Among one-hundred and twenty patients with LAPC treated at our institution with initial
chemotherapy followed by curative chemoradiotherapy (CRT) from July 2013 to January 2019,
a secondary analysis from two prospective protocols with baseline 18F-FDG PET/CT was conducted
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in fifty-eight patients. Criteria for inclusion in the study were as follows: histological diagnosis of
pancreatic adenocarcinoma, locally advanced non-metastatic disease, baseline 18F-FDG PET/CT and no
history of other malignancy within 5 years, age >18 years. Patients had to show sufficient hepatic, renal,
cardiac and bone marrow reserve and be able to tolerate induction chemotherapy and subsequent CRT.
Patients eligible for surgery were automatically excluded from the study. Patients underwent complete
pre-treatment evaluation, including clinical history and physical examination, laboratory exams
(complete blood count, chemistry and CA 19-9), clinical staging based on multi-detector thin-slice
multiphase contrast enhanced CT scan optimized for pancreatic imaging, laparoscopy with peritoneal
washing and 18F-FDG PET/CT scan. Lymph nodes measuring < 1 cm in maximum transverse diameter
on CT scan were considered as metastasis-positive only when characterized by increased 18F-FDG
uptake at PET/CT scan. The lesions were judged as locally advanced unresectable tumours by our
multidisciplinary gastrointestinal tumour board in accordance with NCCN Guidelines (Version 2.2018).
The study was approved by the independent Ethics Committee of our university, in accordance with
the principles of the Declaration of Helsinki. All patients provided written informed consent. This trial
was registered at ClinicalTrials.gov with Identifier NCT02984501.
2.2. Treatment
All patients received a therapeutic protocol that provided initial chemotherapy followed by CRT.
For induction chemotherapy, two regimens were used during the enrolment period: gemcitabine
1000 mg/m2 and oxaliplatin 100 mg/m2, and FOLFIRINOX scheme (oxaliplatin 85 mg/m2, irinotecan
180 mg/m2, leucovorin 400 mg/m2, fluorouracil 2400 mg/m2). In both schedules, chemotherapy was
administered every 14 days for four doses. For patients without disease progression detected
by the re-staging CT scan, chemotherapy was followed by CRT. For the study population,
a four-dimensional CT simulation was performed, when possible, with respiratory training to reduce
internal motion. The Clinical Target Volume (CTV) included tumour and affected nodes for a total dose
of 59.4 Gy. It targets also peripancreatic lymph nodes at risk with a dose of 45 Gy with conventional
fractionation. The Planning Target Volume (PTV) was obtained by expanding the CTV with a 1 cm
margin in all directions to account for set-up error. Treatments were delivered with a multileaf
collimator and a multifield isocentric technique (Varian Medical System). All patients received
concurrent chemotherapy with gemcitabine 600 mg/m2 weekly. Four weeks after the completion of
CRT, patients underwent clinical and imaging evaluation. Tumour response was defined in accordance
with the World Health Organization (WHO) definition through CT scan. Patients were followed-up on
in accordance with their clinical course every three months through a standard surveillance protocol;
thereafter, and the intervals were extended to six months after two years.
2.3. 18 F-FDG PET/CT Acquisition and Analysis
All pre-treatment PET/CT were performed at a single PET/CT Centre, 60± 10 min after the injection
of 236 ± 45 MBq of 18F-FDG, according to the body mass index, from the skull base to mid-thigh
region, using an integrated PET/CT device (Gemini GXL by Philips Medical System, Cleveland,
OH, USA, or Biograph mCT by Siemens Healthineers, Chicago, IL, USA). All patients fasted for
at least 6 h, presented blood glucose level < 150 mg/dL and were in optimal hydration state (i.v.
administration of 500 mL of saline solution) at the time of tracer injection. An X-ray scout was
performed to define the spatial range of acquisition, as well as a low-dose CT scan (120Kv, 50–80 mA)
for photon attenuation correction and fusion with PET images for anatomical localization of functional
finding. PET scans were produced in 3D mode, with an acquisition time of 2–3 min per bed position,
and reconstructed with iterative algorithms. Qualitative and semi-quantitative evaluation of PET
images was performed by two independent nuclear medicine physicians (who were informed of
all clinical and imaging information available at staging, but not made privy to the patients’ final
outcome). Any focal increase in 18F-FDG outside normal distribution or higher than the surrounding
physiological uptake at the first visual evaluation was considered an abnormal finding (see Figure 1
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as representative case). Any disagreement was resolved by consensus. A 3D Volume of Interest (VOI)
was manually placed over the primary tumour and the corresponding SUVmax, defined as maximum
activity concentration (kBq/mL) in the VOI adjusted to the injected activity (MBq) and body weight
(Kg), was measured applying the EQ·PET reference-based quantification technology (developed
by Siemens Healthineers) [15]. The MTV (expressed in cm3) was measured using a threshold of
40% of the SUVmax, visually checking the success of tumour delineation, with the TLG calculated
as the product of the SUVmean and the MTV.
∙
Figure 1. Transaxial low-dose co-registered CT (A), PET (B) and fused PET/CT (C) images show
increased 18F-FDG uptake in the pancreatic tumoural lesion (C).
2.4. Statistical Analysis
All study sample characteristics were summarized with descriptive statistics. Continuous variables
were reported as mean and standard deviation or median (with range). Early progression (EP) was
defined temporally as a progression at the first evaluation, at 3 months from the start of treatment.
EP was evaluated by CT scan. Local progression (LP) was defined as progression in any time at the site of
primary disease and RECIST criteria were used. Overall survival (OS) was determined from the day of
the histological diagnosis to death, or last follow-up if no event was observed. Progression-free survival
(PFS) was calculated from the start of treatment to the date of progression, or to the last follow-up if
no event occurred. OS and PFS curves were obtained with the Kaplan–Meier method. The receiving
operating characteristics (ROC) analysis was performed to define the cut-off point of SUVmax, MTV,
TLG and CA 19-9 values to use in prediction of early progression, local progression and OS. Areas
under the curve (AUCs) were assessed for all variables. Post-test probability was calculated to evaluate
the advantage of parameter combinations. A p value < 0.05 was considered statistically significant.




From July 2013 to January 2019 fifty-eight patients (F:33; M:25) with locally advanced pancreatic
adenocarcinoma were included in our study. Characteristics of the study population were described
in Table 1. The median age was 64 years (range, 40–79). Pancreatic head was the most common site
of presentation (91%), with 9% of tumours occurring in the body of pancreas. The mean serum CA
19-9 value among all patients was 1630 U/mL (range, 11 to 8945 U/mL). In our population, 10 patients
(17%) did not show any increase in CA 19.9 value (<37 U/mL). Twenty patients (34.5%) had a severe
obstructive jaundice at diagnosis. Jaundiced patients before treatment underwent biliary drainage.
In these patients, CA19-9 values were included in the study once the jaundice was resolved, and before
starting the treatment. With regard to pre-treatment 18F-FDG-PET/CT, the mean interval time between
PET/CT and the beginning of treatment was 16 days (range, 2–40 days); the mean values of SUVmax,
MTV and TLG of primary tumours were 6.6 ± 3.6, 20.4 ± 15.3 cm3, and 87.2 ± 79, respectively.
The median follow-up for all patients was 12.8 months (range, 2.6 to 92.9 months). In one patient
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the first re-staging was earlier than planned for the clinical suspicion of progression. At the time of
last evaluation, seventeen patients were alive. Twenty patients (34.5%) developed early progression
at the first evaluation (six patients with local progression, eighteen patients with distant metastases, six
patients with both). Overall, in thirty-nine patients (67%) a disease progression was reported during
the follow-up period. Of these, fifteen patients experienced local progression, thirty-five patients had
distant metastases, eleven patients had both. For the entire cohort of patients, the median OS and PFS
were 14.2 months and 13.6 months, respectively. OS and PFS at 1 year were 71% and 54%, respectively.
Table 1. Patients’ characteristics.
























3.2. ROC Curves and Post-Test Probability Analysis
By ROC curve analysis, CA 19-9 levels, SUVmax, MTV and TLG values of primary tumour were
independently tested to predict EP, LP and OS. Table 2 summarizes AUCs for each variable. ROC
comparison curves of variables predicting EP, LP and OS are shown in Figure 2.
Cancers 2020, 12, 2016 6 of 10
Table 2. Receiver operating characteristic (ROC) analysis for predictors of Early Progression (EP), Local
Progression (LP) and Overall Survival (OS). The variables analyzed were CA 19-9 levels, the maximum
standardized uptake value (SUVmax), the metabolic tumour volume (MTV), the total lesion glycolysis
(TLG) of primary tumours. AUC, area under curve; CI, confidence interval. ns, not significant.
Variables and EP AUC 95% CI




Variables and LP AUC 95% CI




Variables and OS AUC 95% CI




Figure 2. ROC curve comparison of predictors of Early Progression (EP) (A), Local Progression (LP)
(B), and Overall Survival (OS) (C). The variables analyzed were CA 19-9 levels, the metabolic tumour
volume (MTV), the total lesion glycolysis (TLG) and the maximum standardized uptake value (SUVmax)
of primary tumour.
For early progression (EP), CA 19-9 level was the best marker to identify patients at higher risk
with an Odds Ratio (OR) approximately six times higher when CA 19-9 was over 698 U/mL. In fact, CA
19-9 value > 698 U/mL identified EP with a Positive Predictive Value (PPV) of 61%, with a significant
OR of 5.96 (95% CI, 1.66 to 19.47, p = 0.005). Adding other PET parameters such as MTV>32 cm3,
SUVmax > 9 and TLG >103 consecutively, PPV was increased from 61% to 95% (Table 3).
For local progression (LP), the most significant parameter was TLG. A TLG value of over 177
indicated patients at higher risk of local progression, with a positive predictive value of 83%, and was
associated with a significant OR of 9.75 (95% CI, 1.64 to 57.87, p = 0.012). When adding to TLG >177
the evaluation of the other two PET-derived parameters (MTV and SUVmax), when MTV is > 17 cm3
and SUVmax >6.5, the PPV further increased from 83% to 94% (see Table 4).
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Table 3. Predictors of Early Progression (EP). The variables analyzed were CA 19-9, the maximum
standardized uptake value (SUVmax), the metabolic tumour volume (MTV), the total lesion glycolysis
(TLG) of primary tumours. LR+, likelihood-ratio positive; PPV, Positive Predictive Value.
Variables and EP LR+ PPV (%)
CA 19-9 >698 3.23 61
MTV >32 2.50 55
SUVmax >9 2.80 58
TLG >103 1.78 47
Variables Combination and EP PPV (%)
CA 19-9 >698 +MTV >32 79
CA 19-9>698 +MTV >32+ SUVmax >9 91
CA 19-9>698 +MTV >32+ SUVmax >9 + TLG >103 95
Table 4. Predictors of Local Progression (LP). The variables analyzed were the maximum standardized
uptake value (SUVmax), the metabolic tumour volume (MTV), the total lesion glycolysis (TLG) of
primary tumours. LR+, likelihood-ratio positive; PPV, Positive Predictive Value.
Variables and LP LR+ PPV (%)
TLG >177 14 83
MTV >17 1.65 37
SUVmax >6.5 1.87 65
Variables Combination and LP PPV (%)
TLG >177 plus MTV >17 89
TLG >177 plus MTV >17 plus SUVmax >6.5 94
For OS, the most significant parameter was MTV. MTV over 14 cm3 was an indication of patients
at higher risk of death with a PPV of 88% and was associated with an OR of 3.12 (95% CI, 0.9 to 10.83,
p = 0.07). Adding to MTV >14 cm3 the evaluation of TLG, with TLG >167, PPV was increased from
88% to 96%; no significant difference in PPV was observed when also adding SUVmax value (cut-off:
4) (see Table 5).
Table 5. Predictors of Overall Survival (OS). The variables analyzed were the maximum standardized
uptake value (SUVmax), the metabolic tumour volume (MTV), the total lesion glycolysis (TLG) of
the primary tumours. LR+, likelihood-ratio positive; PPV, Positive Predictive Value.
Variables and OS LR+ PPV (%)
MTV >14 2.03 88
TLG >167 3.51 71
SUVmax <4 1.28 48
Variables combination and OS PPV (%)
MTV >14 plus TLG >167 96
MTV >14 plus TLG >167 plus SUVmax <4 97
4. Discussion
In this secondary analysis of prospective data, a bio-imaging signature of clinical outcomes
after integrated chemo-radiotherapy for patients with LAPC was identified. This signature was
based on the combination of 18F-FDG PET/CT semiquantitative parameters (SUVmax, MTV, TLG)
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and serum CA 19-9 level, and achieved a performance of over 90%. Serum CA 19-9 level, TLG
and MTV values of the primary tumour before treatment resulted the best significant predictors of
early progression, local progression and OS, respectively. Moreover, the combination of these variables
is a stronger predictor of clinical outcome than the single parameter. PET-derived parameters and their
prognostic role in pancreatic cancer patients treated by CRT have already been shown in several
studies [13,16–18]. The findings of the meta-analysis of Zhu et al. [13] confirmed that PET-derived
parameters at pre-treatment 18F-FDG PET/CT, despite the methodological and clinical heterogeneity
observed across the included studies, might be prognostic factors in patients with pancreatic cancer,
potentially useful to stratify patient risk in terms of survival and disease control: high MTV values
were significant predictors of poor OS (HR 1.56, 95% CI, 1.13–2.16; p = 0.007) as were high TLG values
(HR 1.70, 95% CI, 1.25–2.30; p = 0.01). Xu et al. [12] evaluated patients who received 18F-FDG PET/CT
before radical pancreatectomy. In this report, TLG and MTV were significantly correlated to baseline
serum CA19-9 level (p< 0.001 for TLG, p= 0.001 for MTV). Multivariate analysis showed that TLG, MTV
and baseline serum CA19-9 levels were independent risk predictors for both OS and recurrence-free
survival. However, studies on patients receiving chemotherapy and radiotherapy in LAPC have
rarely focused on the combination of CA 19-9 levels and FDG-PET/CT parameters to predict disease
progression, remaining mainly polarised on the association between PET/CT variables and survival.
To the best of our knowledge, our study is the first to analyse this combination. For EP, a CA 19-9 level
>698 U/mL resulted as the best marker to identify patients at higher risk with an OR of 5.96 (95%CI,
1.66–19.47). The combination of this parameter with that derived from FDG-PET/CT strengthened
the positive predictive value of the marker itself, increasing from 61% to 95%. For LP, the most
significant parameter was TLG>177 with a significant OR of 9.75 (95%CI, 1.64–57.87). When combined
with other parameters, its positive predictive value increased from 83% to 94%. For OS, the most
significant parameter was MTV with an OR of 3.12 (95% CI, 0.9–10.83). The combination of this marker
with other PET-derived parameters increased the positive predictive value to 97%. Regarding metabolic
parameters, in our study, no correlation between SUVmax of the tumour and EP, LP and OS was found.
Therefore, MTV and TLG taken individually resulted as better predictors of progression and OS than
SUVmax. In this regard, our results are in line with previous studies supporting the prognostic role of
volumetric PET parameters in pancreatic cancer patients, with less concordant results on the prognostic
value of SUVmax [19–21]. In addition, compared to MTV and TLG, adding the SUVmax of the primary
tumours to the other variables leads to an increase in prediction of early and local progression, but with
no evident contribution to overall survival. Furthermore, this finding seems to suggest an overall major
prognostic role of the PET volumetric parameters over SUVmax. Although all of these PET parameters
are used to measure the metabolic activity of a lesion, a possible explanation for the observed different
prognostic values may be related to their inherent differences in methodology. Indeed, SUVmax
represents the maximum voxel value of tracer concentration within the tumour (i.e., the metabolic
activity value from only one voxel), whereas MTV and TLG are expressions of the whole tumour
metabolic burden, also taking into consideration heterogeneous intralesional distribution of tracer
uptake [10].
This study has several limitations. First, these findings are the result of a secondary analysis
rather than of a prospective assignment. Second, the study population is relatively small. However,
all patients had been enrolled in prospective integrated chemo-radiotherapy trials and the 18F-FDG
PET/CT scan had been performed in each case with the same acquisition protocols and uniformly
analysed by the same nuclear medicine physicians. Third, a limitation to CA 19-9 serum level
evaluation in pancreatic cancer includes false negative results in Lewis negative phenotype (observed
in 5–10% of patients with pancreatic cancer) [14]. In our experience, patient stratification, considering
both CA 19-9 levels and 18F-FDG PET/CT parameters such as MTV and TLG before treatment,
is able to effectively predict whether a particular patient with LAPC will or will not have early
progression or disease progression during the course of treatments. In the future, the availability
of this signature before treatment could allow oncologists to personalize treatments, for instance by
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intensifying chemotherapy as initial therapy or modifying radiation total dose, fractionation or drugs,
in combination with radiotherapy, or even selecting patients for consolidation therapy. Future planned
studies at our institution include the prospective validation of these results in a larger population,
as well as the integration of radiomics biomarkers.
5. Conclusions
The combination of 18F-FDG PET/CT parameters and CA19-9 levels before treatment is promising
for identifying patients at a higher risk of disease progression. These prognostic biomarkers might
be useful for the design and development of future trials or the selection of personalized therapeutic
options, possibly simplifying the management and improving the prognosis of LAPC patients.
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